New combo aims to fight Drug-Resistant prostate cancer

NCT ID NCT05534646

Recruiting now Disease control Sponsor: Edwin Posadas, MD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding carotuximab to the standard drug apalutamide can help men with metastatic castration-resistant prostate cancer that has stopped responding to other treatments. About 100 participants will receive either apalutamide alone or the combination. The study first checks safety in 10 people, then measures how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: apalutamide and carotuximab
What this could lead to: If this works, it could offer a new treatment option for men with advanced prostate cancer that has stopped responding to current therapies.
What could go wrong: This is an early phase 2 trial with only 100 participants, so results may not apply to everyone. The combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Cedars-Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States
City of Hope
RECRUITING

Duarte, California, 91010, United States
Huntsman Cancer Institute and Hospital
RECRUITING

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.